About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Driver

Strange, I keep watching this share more than the others, could make some good money on this 1p would be a good start ! : )

no not on holiday.. just letting you guys get on with it, news out this week, gonna be huge.. massive..

almost falic like

smiler
Relax ERX will see us all right the share will move on news and I think there is plenty to come more news on its lead compound ERX3722 and the discussions with a developmental company to prepare it for a future phase 1 clinical trials.
Also more compounds for colorectal tumours that it is currently working on. All good stuff.

September 26, 2006 07:03 AM Eastern Time
Alnylam Grants Quark a License to Develop and Commercialize
Two RNAi Therapeutic Products
Target-Specific Licenses for RNAi Intellectual Property Granted Under Alnylams InterfeRx Program -
BIOWIRE2K
CAMBRIDGE, Mass. & FREMONT, Calif.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has granted Quark Biotech, Inc. InterfeRx licenses to discover, develop, and commercialize RNAi therapeutics targeting the p53 and RTP801 genes for certain diseases. Quark has filed investigational new drug (IND) applications for RNAi therapeutics for both targets, in the case of p53 for the treatment of renal failure, and in the case of RTP801 for the treatment of ocular diseases, specifically macular degeneration. Detailed financial terms were not disclosed, but include upfront, annual, and milestone payments, as well as royalties on sales of any products covered by the licensing agreements. Simultaneously, Quark has agreed to withdraw its support of opposition to the Kreutzer-Limmer patent series currently granted in Europe.

We are very pleased to provide Quark with a license to Alnylam intellectual property for its innovative RNAi therapeutic programs, said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam. With these two licenses, we have now granted six InterfeRx licenses to date, and 12 licenses in total for therapeutic RNAi applications. With the recent strengthening of our patent estate, we expect that companies working in the area of RNAi therapeutics will continue to seek licenses to our intellectual property. In fact, we anticipate that into next year, a significant number of clinical-stage RNAi therapeutic programs will be licensed under Alnylam intellectual property.

RNAi therapeutics represent a promising approach as a new class of drugs for unmet medical needs wherever the disease targets are otherwise practically un-druggable with todays medicines, said Dr. Daniel Zurr, Chief Executive Officer of Quark. Quarks creative way to discover new targets and concepts for treatment of devastating diseases, combined with an RNAi approach, have yielded very encouraging early results with our p53 and RTP801 drugs. We are dedicated to help society with innovative medicines by moving from novel gene targets to unique compounds and eventually commercial products. In our comprehensive review of the intellectual property landscape for the commercialization of RNAi therapeutics, it was clear that a license to Alnylam patents is required for these exciting programs, and were pleased to have access to these assets.

Alnylam has built a leading portfolio of issued or granted patents in the worlds major pharmaceutical markets that broadly claim fundamental features for all RNAi therapeutics, including the structural and functional properties of synthetic RNAi therapeutic products. The recognized potential of RNAi to provide the basis for an entirely new class of drugs to treat a broad range of human diseases has created a high level of interest among biopharmaceutical companies in gaining access to this intellectual property. Alnylam created the InterfeRx licensing program to grant licenses under this intellectual property to biotechnology and pharmaceutical companies wishing to pursue RNAi therapeutics against specific targets outside Alnylams core strategic interests. In addition to Quark, Alnylams InterfeRx licensees include Calando Pharmaceuticals, Nastech Pharmaceutical Company, GeneCare Research Institute Co., and, under an option agreement, Benitec Ltd.

Quarks RNAi therapeutic that specifically targets p53 is being developed to reduce tubular damage and preserve kidney function. The novel concept of the temporary and reversible inhibition of p53 to prevent apoptosis in normal cells following ischemia-reperfusion injury was first described by Quark in 1999 in the journal Science [Science 285, 1733-37 (1999)] and is covered by broad issued U.S. patents. Extensive animal studies have shown that the drug protects the animals from ischemia/reperfusion-induced acute kidney injury.

Quarks second RNAi therapeutic targets the gene RTP801. Quark reported the discovery of RTP801 in 2002 and was granted several U.S. patents covering the gene, its encoded protein and their inhibition to treat serious diseases. The inhibition of the RTP801 target has been shown to have beneficial effect in a number of oxidative (hypoxic) injuryrelated disease models. Extensive animal studies have shown that the drug protects the animals from the three hallmarks of macular degeneration: retinal neuronal death, blood vessel regeneration, and vascular leakiness.

About RNA Interference (RNAi)

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.

About Alnylam

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection, which is the leading cause of hospitalization in infants in the U.S. The companys leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. Alnylam is honored to be the emerging/mid-cap company recipient of the 2006 James D. Watson Helix Award, the biotechnology industrys award for outstanding achievement. For more information, visit www.alnylam.com.

About Alnylam Intellectual Property (IP)

Alnylams IP estate includes issued or granted fundamental patents in the worlds major pharmaceutical markets that claim the broad structural and functional properties of synthetic RNAi therapeutic products. As it applies to the U.S. and Europe, these include:

The Tuschl II 704 patent (U.S. Patent No. 7,056,704) issued in June 2006, which broadly covers methods of making siRNAs to silence any and all disease targets;
The Tuschl II 196 patent (U.S. Patent No. 7,078,196) issued in July 2006, which broadly covers methods of making siRNAs with or without chemical modifications;
The Kreutzer-Limmer I 623 patent (EP 1144623) granted in August 2002, and upheld in June 2006, covering methods, medicaments, and uses of siRNAs having, among other structural features, a length of 15-21 base pairs;
The Kreutzer-Limmer I 945 patent (EP 1214945) granted in June 2005, covering compositions, methods, and uses of siRNAs with a length between 15 and 49 nucleotides;
Additional fundamental patents and patent applications licensed to Alnylam on an exclusive or non-exclusive basis, including those of Crooke (U.S. Patent Nos. 5,898,031 and 6,107,094), Fire and Mello (U.S. Patent No. 6,506,559), and Glover et al. (EP 1230375); and,
Several divisional patent applications pending of the aforementioned issued or granted patents and additional patent applications pending including Tuschl I.
In addition, Alnylam has a broad worldwide license for RNAi therapeutics from Isis Pharmaceuticals, Inc. for more than 150 issued patents pertaining to specific chemical modification of oligonucleotides used to introduce drug-like properties in siRNAs. These include:

Phosphorothioate and 2'-O-methyl modifications (Buhr, U.S. Patent No. 6,476,205); and,
2'-Fluoro modifications (Cook, U.S. Patent Nos. 5,670,633; 6,005,087; and 6,531,584).
Alnylam invites interested licensees to view issued or granted claims for these and other key Alnylam patents at www.alnylam.com/patent-estate.

About Quark

Quark Biotech, Inc. is a privately held development-stage, biopharmaceutical company headquartered in Fremont, California. Through innovative combination of gene silencing and DNA microarray technology, Quark has pioneered and patented its BiFARTM platform for high-throughput functional profiling, allowing significant advances in the identification of target genes and proteins. This technology allows the company to develop conceptually novel drugs that provide previously unavailable benefits to patients. Quark is currently investigating novel targets identified using this enabling foundation technology. Quark has focused development efforts on treatment of fibrotic and ischemic diseases of the eye, kidney and lungs, in indications with clear unmet medical needs. Quark corporate product development teams and research facilities are based in Fremont with additional research facilities in Ness-Ziona, Israel. Additional information is available at www.quarkbiotech.com.

Driver

away again tomorrow till 0700 to 2000 so bound to get some news ! just my luck

smiler
You never know, all buys again today.

Driver

whats all that crap ph has posted is it anything to do with erx ??

smiler
I dont read his stuff properly not.

Say No MORE !!

Nothing new just looks good.

Biotechnology Ireland
http://www.biotechinfo.ie/pooled/articles/BF_NEWSART/view.asp?Q=BF_NEWSART_216242

EXPECT NEWS THIS WEEK.. TODAY OR TOMORROW BY MY RECKONING

Article Preview
Researchers' data from the United Kingdom, Germany and United States advance cancer treatment research

Vaccine Weekly - Sep. 13, 2006
2006 SEP 13 - (NewsRx.com) -- Data on cancer treatment are outlined in reports from the United Kingdom, Germany and United States.

Study 1: A new anticancer glycolipid monoclonal antibody, SC104, directly induces tumor cell apoptosis.

According to recent research from England, "A novel monoclonal antibody was raised by immunization of mice with colorectal tumor cell lines. The fusion was screened by immunohistochemistry for binding to primary colorectal tumors. Subsequent analysis on primary disaggregated colorectal tumors show that the antibody recognizes a cell surface antigen expressed by the majority of colorectal tumors."

"Antigen characterization has shown that the antibody ...

http://www.therapeuticsdaily.com/news/article.cfm?contentValue=1078531&contentType=sentryarticle&channelID=28


EIRX THERAPEUTICS PLC ("EIRX")

POTENTIAL NEW THERAPIES FOR COLORECTAL & OTHER CANCERS


Cork, Ireland, 10th January, 2006 EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to announce the filing of patent applications describing a novel class of drug candidates with potential value as treatments for a range of cancers including colorectal and breast tumours. This class of molecule is structurally dissimilar to the class of molecules for which patent applications were made in August 2005, thus ensuring a deeper pipeline of development for the treatment of colorectal and breast cancer.

Exploiting the insight afforded to them through their ALIBITM genomics platform, EiRx scientists developed EnPADTM technology to target APC-b-catenin signalling, a cellular control pathway known to play a major role in the majority of cases of colorectal cancer, as well as in several other tumour types. A custom-designed EnPADTM cell line was used to screen a focused library of drug-like, kinase inhibitor compounds, resulting in the discovery of a series of related compounds with selective activity against transformed cell types including colorectal and breast cancer cell lines. The EnPADTM technology development programme was funded in part by the Marie Curie Transfer Of Knowledge grant.

Commenting on the discovery, EiRxs Chief Scientific Officer Prof Tom Cotter said: The company's EnPADTM technology has again proven its ability to identify novel classes of molecules with selective biological activity. The class of molecules filed in the current patent applications are structurally quite different to those that were the subject of the earlier patent applications in August 2005. As a result we are in the enviable position of moving two chemical scaffolds through preclinical with the potential to treat these socio-economically important diseases.

EiRx Chairman John Pool said: Not only does filing a second class of molecule with activity against colorectal and breast cancer endorse our EnPADTM approach in drug discovery; it also demonstrates that EiRx has set its sights firmly on the identification and development of novel molecules to treat cancer. Having two series of molecules in preclinical development, both with the potential to treat colorectal and breast cancer, demonstrates that EiRx has the potential to rapidly become a key player in these very considerable therapeutic markets.

Someone has just sold 40 million shares.

it was a broker to broker you numbskull, news coming..

40mil buy just gone through now

Laurie
Take no notice of PH thats his way, no sells today again and a broker to broker just as PH (news international) says.

Driver

Glad to see I did not miss much ! I must say glad I did not get any HML at 4.50 I almost got some, I think I will stick with ERX ! : )

smiler
Yep HML looks a dead duck at the moment may be a lesson to learn for the future with ERX if we have a massive sp rise, or when that is.

Driver

TO True, we live and learn, my big loss this year so far is Aisa Energy still suspended !! lets hope we all can make a few quid on erx : )

Doctors hail lung cancer breakthrough




28 September 2006
An experimental drug that extends the lives of lung cancer patients by a third has impressed doctors, who say that it is one of the first signs of progress against the disease.

Lung cancer is among the most lethal of all cancers and claims more lives each year than any other. Only five per cent of patients survive more than five years.

Efforts to find an effective treatment have failed and unlike other cancers, such as breast cancer, the death rate has not changed for more than a decade. A trial of the as yet unnamed drug, known as AS1404, in 70 patients with non-small cell lung cancer (NSCLC), the commonest kind, found they lived for 14 months on average compared with 8.8 months for those given chemotherapy alone.

Although the extra five months gained is small in absolute terms, it is a significant improvement, suggesting a genuine benefit from the drug. More than 26,000 people in Britain die from NSCLC each year.

The drug, discovered by researchers in New Zealand and developed by the UK biotechnology company, Antisoma, with backing from Cancer Research UK, is one of a new class of compounds called vascular disrupting agents. These work by destroying blood vessels that supply solid tumours on which the tumours depend to survive and grow.

The success of the phase II study lays the ground for a larger phase III trial, the outcome of which will determine whether the drug is licensed as safe and effective. AS1404 has already been shown to be effective in phase II trials of prostate and ovarian cancer.

Mark McKeage of the University of Auckland, one of the researchers, said: "It is great to see this large survival benefit with AS1404 in lung cancer patients. This makes me feel very optimistic as we progress into phase III testing."

Professor Alex Markham, chief executive of Cancer Research UK, said: "Our drug development team played an integral role in the early development of the drug and we're delighted with this news. We look forward to seeing how the drug performs in a much larger number of patients."

The charity has set up a company to raise the number of undeveloped new treatments by putting them into clinical trials. Since 1982, more than 100 agents have been put into trials.

"Over the next five years we plan to double our activity and speed up the drug development process, getting even more new drugs into clinical trials," Professor Markham said.

* Living near heavy industry may raise the risk of lung cancer. A study of women in Teesside, who lived within three miles of a chemical production complex at Billingham for at least 25 years, found they were twice as likely to develop the disease than others, after smoking and other factors were taken into account.
http://www.belfasttelegraph.co.uk/lifestyle/health_beauty/story.jsp?story=708067

Sonus Pharmaceuticals Initiates Phase 1 Clinical Trial for ...
Genetic Engineering News (press release), NY - 1 hour ago
... "This promising compound may have the ... lead oncology product candidate, TOCOSOL Paclitaxel, is currently in a Phase 3 pivotal trial in metastatic breast cancer. ...

Biothera Completes Second Phase I Clinical Trial for Cancer Drug
PipelineReview.com (press release), Spain - 6 hours ago
... I clinical trial for Imprime PGG its lead compound for activating ... and increases in survival in multiple types of cancer, including breast, lung and ...